2 Results Found

Advanced Search

Select all

Results per page

Select all

Article

303 Views

11 Pages

Enhancing Herpes Zoster Vaccination Rates Among Oncology Outpatients: Impact of an In-House Vaccination Initiative

Alberto Giuseppe Agostara,
Silvia Della Torre,
Sara Di Bella,
Michela Pelliccione,
Paola Candido,
Valeria Smiroldo,
Davide Toniolo,
Francesca Zannier and
Roberto Bollina

Cancers2025, 17(21), 3502;https://doi.org/10.3390/cancers17213502

-

30 October 2025

Background: Herpes zoster (HZ) poses significant risks to immunocompromised individuals, particularly cancer patients receiving systemic therapies. The recombinant zoster vaccine (RZV, Shingrix®) provides strong and durable protection against HZ...

Full Article

Article

5 Citations

2,305 Views

6 Pages

Herpes Zoster Vaccination Rates in Hematological and Oncological Patients—Stock Taking 2 Years after Market Approval

Til Ramón Kiderlen,
Katrin Trostdorf,
Nicola Delmastro,
Arne Salomon,
Maike de Wit and
Mark Reinwald

Healthcare2022, 10(8), 1524;https://doi.org/10.3390/healthcare10081524

-

12 August 2022

Background: Vaccinations have the potential to significantly lower the burden of disease for many major infections in the high-risk population of hematological and oncological patients. In this regard Shingrix®, an inactivated Varicella Zoster Vi...

Full Article